References

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 182 CE courses, most popular		$109Add to cart
Pick Your Courses
Up to 8 CE hours		$55Add to cart
Individual course$25Add to cart
The page below is a sample from the LabCE course Latent Mycobacterium tuberculosis Infection and Laboratory Test Methods. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Latent Mycobacterium tuberculosis Infection and Laboratory Test Methods (online CE course)
References

Baseline tuberculosis screening and testing for health care personnel. (2023). Centers for Disease Control and Prevention. https://www.cdc.gov/tb-healthcare-settings/hcp/screening-testing/baseline-testing.html
CDC releases “Reported Tuberculosis in the United States, 2023.” (2024). Centers for Disease Control and Prevention. https://www.cdc.gov/tb/php/dear-colleague-letters/2024-reported-tuberculosis-2023.html
Clinical testing guidance for tuberculosis: interferon gamma release assay. (2024). Centers for Disease Control and Prevention. https://www.cdc.gov/tb/hcp/testing-diagnosis/interferon-gamma-release-assay.html
Core curriculum on tuberculosis: What the clinician should know. (2024). Centers for Disease Control and Prevention. https://www.cdc.gov/tb/hcp/education/core-curriculum-on-tuberculosis.html
Division of Tuberculosis Elimination. (2024). Progress towards TB elimination, United States, 1982–2023. Taken from slide set: Tuberculosis (TB) in the United States, 1993–2023. Centers for Disease Control and Prevention. https://www.cdc.gov/tb-surveillance-report-2023/resources/slide-set.html
Global Tuberculosis Programme & Guidelines Review Committee. (2018). Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. World Health Organization. https://www.who.int/publications/i/item/9789241550239
History of World TB Day. (2024). Centers for Disease Control and Prevention. https://www.cdc.gov/world-tb-day/history/index.html
Latent tuberculosis infection: A guide for primary health care providers. (2020). Centers for Disease Control and Prevention. https://www.cdc.gov/tb/media/pdfs/Latent-TB-Infection-A-Guide-for-Primary-Health-Care-Providers.pdf
Ledesma, J., Ma, J., Zheng, P., et al. (2021). Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis. BMC Infect Dis, 467. https://doi.org/10.1186/s12879-021-06141-4
Meermeier, E., Lewinsohn, D. (2018). Early clearance versus control: What is the meaning of a negative tuberculin skin test or interferon-gamma release assay following exposure to Mycobacterium tuberculosis? Faculty Rev-664. doi:10.12688/f1000research.13224.1
Pai, M., Denkinger, C., Kik, S., et al. (2014). Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev., 27(1):3-20. doi:10.1128/CMR.00034-13
QuantiFERON®-TB Gold Plus (QFT®-Plus) Package Insert. (2023). Qiagen. https://www.qiagen.com/us/resources/download.aspx?id=ac068fc7-a994-4443-ac7c-dda43ce2bc5e&lang=en
Ra, S., Lyu, J., Choi, C., et al. (2011). Distinguishing tuberculosis from Mycobacterium avium complex disease using an interferon-gamma release assay. Int J Tuberc Lung Dis., 15(5):635-640. doi:10.5588/ijtld.10.0485.
Stockbridge, E., Loethen, A., Annan, E., & Miller, T. (2020) Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data. PLOS ONE, 15(12): e0243102. https://doi.org/10.1371/journal.pone.0243102
T-SPOT®.TBPackage Insert. (2020). Oxford Immunotec. https://www.tspot.com/wp-content/uploads/2020/09/TB-PI-US-0001-V8.pdf
Tuberculosis. (2024). World Health Organization. https://www.who.int/news-room/fact-sheets/detail/tuberculosis
Update of WHO guidelines on the management of latent TB infection. (2019). World Health Organization (WHO). https://www.who.int/news/item/07-01-2019-update-of-who-guidelines-on-the-management-of-latent-tb-infection